ADMA Biologics logo
ADMA Biologics ADMA
$ 8.24 -2.6%

Quarterly report 2026-Q1
added 05-06-2026

report update icon

ADMA Biologics Financial Statements 2011-2026 | ADMA

Annual Financial Statements ADMA Biologics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

3.78 B 3.7 B 1.21 B 607 M 197 M 191 M 222 M 142 M 87.5 M 62.1 M 62.8 M 572 M 55.8 M - - -

Shares

238 M 233 M 224 M 198 M 140 M 86.1 M 54.3 M 45.2 M 22.9 M 12.2 M 10.4 M 73.8 M 6.53 M - - -

Historical Prices

15.9 15.9 5.4 3.07 1.41 1.95 4 2.39 3.21 5.12 8.07 11.2 7.8 - -

Net Income

147 M 198 M -28.2 M -65.9 M -71.6 M -75.7 M -48.3 M -65.7 M -43.8 M -19.5 M -18 M - -15.5 M -7.3 M -26.5 K -

Revenue

510 M 426 M 258 M 154 M 80.9 M 42.2 M 29.3 M 17 M 22.8 M 10.7 M 7.18 M - 3.07 M 1.12 M - -

Cost of Revenue

217 M 207 M 169 M 119 M 79.8 M 61.3 M 39.5 M 42.2 M 29.2 M 1.61 M - - - - - -

Gross Profit

293 M 220 M 88.9 M 35.3 M 1.17 M -19.1 M -10.2 M -25.2 M -6.4 M 4.3 M 2.87 M - 1.04 M 449 K - -

Operating Income

191 M 139 M 21.6 M -39.4 M -58.4 M -64.9 M -41.4 M -60.3 M -39.3 M -17.3 M -15.5 M -16 M -15 M -7.91 M -4.62 M -

Interest Expense

-212 K -193 K 25 M 19.3 M 13.1 M 12 M 8.99 M 5.52 M 3.29 M 2.24 M 1.84 M 1.29 M 618 K 30.7 K 1.6 M -

EBITDA

199 M 147 M 29.2 M -33 M -53.6 M -64.2 M -40.6 M -59.4 M -37.2 M -16.9 M -15 M - -14.8 M -7.73 M -26.5 K -

Operating Expenses

101 M 80.6 M 67.3 M 74.6 M 59.5 M 45.8 M 31.3 M 35.1 M 32.1 M 21.6 M 18.4 M 22 M 16.1 M 8.36 M 26.5 K -

General and Administrative Expenses

91.6 M 74.1 M 59 M 52.5 M 42.9 M 35.1 M 25.9 M 22.5 M 18.1 M 8.49 M 6.75 M - 4.37 M 3.14 M 26.5 K -

All numbers in USD currency

Quarterly Income Statement ADMA Biologics

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

236 M 239 M 241 M 238 M 237 M 235 M 232 M 229 M 226 M 225 M 223 M 222 M 222 M 196 M 196 M 196 M 196 M 134 M 127 M 116 M 105 M 87.7 M 86.3 M 73.8 M 59.3 M 59.3 M 52.2 M 46.4 M 46.4 M 46.4 M 42.7 M 45.3 M 36.7 M 25.8 M 16.4 M 12.9 M 12.9 M 12.9 M 12.1 M 10.7 M 10.7 M 10.7 M 10.7 M 9.86 M 9.29 M 9.29 M 9.29 M 9.29 M 9.29 M 5.87 M 5.87 M 5.87 M 5.87 M 5.91 M 5.91 M 3.36 M 409 K 409 K 409 K 409 K

Net Income

45.3 M 36.4 M 34.2 M 26.9 M - 35.9 M 32.1 M 17.8 M - 2.56 M -6.37 M -6.79 M - -14.9 M -13.8 M -25 M - -17.7 M -18.9 M -18.4 M - -16.9 M -20.2 M -19.2 M - -11.4 M -13.2 M -13.1 M -18 M -15.1 M -14.7 M -17.8 M - -15.2 M -9.04 M -6.54 M - -4.33 M -6.01 M -4.61 M - -5.1 M -4.68 M -3.61 M - -3.38 M -3.96 M -5.9 M - -2.69 M -4.9 M -3.24 M - -3.25 M -1.21 M -597 K -8.33 K -981 K -13.5 K -1.58 M

Revenue

114 M 134 M 122 M 115 M - 120 M 107 M 81.9 M - 67.3 M 60.1 M 56.9 M - 41.1 M 33.9 M 29.1 M - 20.7 M 17.8 M 16 M - 10.3 M 7.79 M 10.2 M - 7.22 M 6.56 M 3.53 M 4.06 M 4.23 M 4.66 M 4.04 M - 4.73 M 3.4 M 2.63 M - 2.94 M 2.27 M 2.12 M - 1.85 M 1.31 M 1.5 M - 1.37 M 1.5 M 1.56 M - 1.11 M 743 K 793 K - 360 K 230 K 4.4 K - - - -

Cost of Revenue

33.7 M 58.6 M 54.8 M 53.7 M - 60.2 M 49.7 M 42.8 M - 42.6 M 43.4 M 40.4 M - 31.4 M 26.1 M 25.4 M - 20.3 M 18.8 M 17.8 M - 11.9 M 13.5 M 16.8 M - 7.92 M 10.5 M 9.41 M 11.1 M 9.16 M 9.65 M 12.2 M - 11.3 M 4.33 M 182 K - 327 K 383 K - - - - - - - - - - - - - - - - - - - - -

Gross Profit

80.8 M 75.6 M 67.2 M 61.1 M - 59.7 M 57.5 M 39.1 M - 24.7 M 16.7 M 16.5 M - 9.66 M 7.77 M 3.66 M - 385 K -1 M -1.72 M - - - - - - - - - - - - - -6.56 M -935 K 1.01 M - 1.2 M 928 K 857 K - 740 K 524 K 593 K - 498 K 560 K 584 K - 381 K 258 K 264 K - 216 K 88.2 K 2.2 K - - - -

Operating Income

58.3 M 51 M 42.8 M 34.9 M - 39.6 M 39.2 M 21.8 M - 8.68 M -473 K -813 K - -9.32 M -9.17 M -14.8 M - -14.4 M -15.6 M -15.2 M - -13.8 M -17.1 M -16.8 M - -9.05 M -11.3 M -13.2 M -16.5 M -13.8 M -13.4 M -16.5 M - -14.4 M -8.4 M -5.94 M - -3.74 M -5.49 M -4.16 M - -4.66 M -3.52 M -3.2 M - -3.04 M -3.59 M -5.68 M - -2.53 M -4.84 M -3.15 M - -3.25 M -1.21 M -1.21 M - -768 K -2.15 M -1.59 M

Interest Expense

-140 K -21 K -108 K -64 K - -56 K -16 K -35 K - -145 K -13 K 6.12 M - 5.58 M 4.57 M 3.39 M - 3.3 M 3.25 M 3.2 M - 3.09 M 3.07 M 2.72 M - 2.65 M 2.07 M 1.54 M 1.44 M 1.4 M 1.36 M 1.32 M - 783 K 642 K 619 K - 606 K 538 K 467 K - 449 K 453 K 476 K - 335 K 343 K 227 K - 163 K 159 K 129 K - 2.65 K 3.1 K 8.49 K - - 240 K 316 K

EBITDA

60.1 M 53 M 44.8 M 36.8 M - 41.5 M 41.1 M 23.7 M - 10.6 M 1.43 M 1.09 M - -7.62 M -7.67 M -13.4 M - -13.2 M -14.5 M -14.1 M - -12.9 M -16.4 M -16.2 M - -8.23 M -10.5 M -12.4 M -16.3 M -12.9 M -12.6 M -15.7 M - -13.6 M -8.12 M -5.82 M - -3.62 M -5.37 M -4.04 M - -4.55 M -3.4 M -3.09 M - -2.98 M -3.54 M -5.64 M - -2.48 M -4.78 M -3.11 M - -3.2 M -1.16 M -1.17 M - -713 K -2.09 M -1.53 M

Operating Expenses

22.5 M 24.6 M 24.4 M 26.2 M - 20 M 18.3 M 17.3 M - 16 M 17.2 M 17.3 M - 19 M 16.9 M 18.5 M - 14.8 M 14.6 M 13.4 M - 24.1 M 24.9 M 27 M - 16.3 M 17.9 M 16.7 M 20.6 M 18 M 18.1 M 20.6 M - 19.2 M 11.8 M 8.57 M - 6.67 M 7.76 M 6.28 M - 6.52 M 4.83 M 4.71 M - 4.4 M 5.09 M 7.24 M - 3.64 M 5.59 M 3.94 M - 3.61 M 1.44 M 1.22 M 8.33 K 768 K 13.5 K 1.59 M

General and Administrative Expenses

26.7 M 21.8 M 22.2 M 24.1 M - 18.6 M 16.6 M 15.6 M - 14.7 M 14.2 M 14.5 M - 12.9 M 12 M 13.7 M - 10.7 M 10.4 M 10 M - 9.12 M 8.7 M 7.93 M - 7.2 M 6.09 M 5.6 M 6.07 M 5.67 M 5.44 M 5.32 M - 4.2 M 4.44 M 4.28 M - 1.78 M 1.72 M 1.71 M - 2.08 M 1.44 M 1.35 M - 1.04 M 1.54 M 1.13 M - 845 K 1.09 M 1.43 M - 1.03 M 737 K 675 K - 261 K 314 K 357 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ADMA Biologics ADMA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ADMA Biologics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.61 2.55 % $ 189 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
BioNTech SE BioNTech SE
BNTX
$ 92.14 1.33 % $ 22.3 B germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.8 7.28 % $ 262 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.72 -0.37 % $ 32.9 M israelIsrael
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 - $ 651 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 32.59 -6.89 % $ 877 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 21.59 -1.86 % $ 280 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.88 -0.93 % $ 213 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
InflaRx N.V. InflaRx N.V.
IFRX
$ 2.61 5.67 % $ 176 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.4 -1.16 % $ 5.6 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 20.86 -0.71 % $ 2.65 B usaUSA